TD 139

Drug Profile

TD 139

Alternative Names: TD-139

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Lund University; University of Edinburgh
  • Developer Galecto Biotech
  • Class Antifibrotics; Small molecules; Thioglycosides
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 01 Dec 2016 Galecto Biotech completes a phase Ib/IIa trial in Idiopathic pulmonary fibrosis in United Kingdom (NCT02257177)
  • 01 Mar 2015 Phase-II clinical trials in Idiopathic pulmonary fibrosis in United Kingdom (Inhalation)
  • 01 Mar 2015 The US FDA approves IND application for TD 139 in Idiopathic pulmonary fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top